Medmix AG, headquartered in Switzerland (CH), is a leading player in the precision dispensing and mixing solutions industry. Founded in 2021, the company emerged from a rich heritage of innovation, focusing on advanced technologies for the healthcare, consumer, and industrial sectors. With a strong presence in Europe, Asia, and the Americas, Medmix offers a diverse range of core products, including high-performance dispensing systems and mixing solutions that stand out for their reliability and efficiency. The company is recognised for its commitment to quality and sustainability, positioning itself as a trusted partner in various markets. Medmix has quickly established itself as a key competitor, leveraging its expertise to deliver tailored solutions that meet the evolving needs of its clients, thereby solidifying its reputation in the global marketplace.
How does Medmix's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Medmix's score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Medmix reported total carbon emissions of approximately 73.6 million kg CO2e, comprising 4,351,000 kg CO2e from Scope 1, 5,880,000 kg CO2e from Scope 2, and 63,355,000 kg CO2e from Scope 3 emissions. This reflects a slight decrease from 2023, where total emissions were approximately 65.6 million kg CO2e, with Scope 1 at 4,381,000 kg CO2e, Scope 2 at 1,214,000 kg CO2e, and Scope 3 at 60,044,000 kg CO2e. In 2022, total emissions were approximately 74.8 million kg CO2e. Medmix has set ambitious climate commitments, aiming for a 50% reduction in absolute Scope 1 emissions by 2030 compared to 2019 levels. Additionally, they have committed to reducing absolute Scope 1 and 2 GHG emissions by 80% by 2029 and achieving a 90% reduction across all scopes by 2050, also from a 2019 baseline. Furthermore, Medmix has pledged to reach net-zero greenhouse gas emissions across its value chain by 2050. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified under the 1.5°C pathway, demonstrating Medmix's commitment to addressing climate change effectively.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 5,408,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,545,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 67,803,000 | 00,000,000 | 00,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medmix has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Medmix's sustainability data and climate commitments